

Commentary

Lymphotoxins: From cytotoxicity to lymphoid organogenesis

Harald von Boehmer

Institut Necker, Institut National de la Santé et de la Recherche Médicale 373, 156 rue de Vaugirard, F-75730 Paris, Cedex 15, France

Tumor necrosis factor (TNF) and lymphotoxins (LT) belong to a family of structurally related cytokines (1) that were originally recognized for their cytotoxic effects on normal or transformed cells (2–4). The genes for the lymphotoxins α (LT α) and β (LT β) as well as for TNF are clustered within the major histocompatibility complex (5–7). Whereas TNF can be expressed and secreted by a variety of cells including lymphocytes, NK cells, and monocytes (1), the lymphotoxins are mostly produced by activated lymphocytes and NK cells (8). TNF exists as a homotrimer that interacts with two TNF receptors, p55 TNFR and p75 TNFR. The lymphotoxins can be found either as homotrimers or heterotrimers. The LT α homotrimer lacks a transmembrane domain. The LT α , β ₂ heterotrimer can be retained at the cell surface because LT β is a type II transmembrane protein (6). The LT α homotrimer binds like TNF to the p55 TNF and p75 TNF receptors (6), whereas the LT α , β ₂ heterotrimer binds to the LT β receptor (3) (Fig. 1). The p55 and p75 TNF receptors are expressed in a variety of tissues including hemopoietic and epithelial cells (9). LT β expression is found in primary and secondary lymphoid tissues but is absent in cells of peripheral blood (9).

A number of studies in mice deficient in either TNF or LT as well as their receptors have now provided persuasive evidence that these cytokines do not only mediate cytotoxic effector functions as their names suggest but are, perhaps more importantly, involved in lymphoid organogenesis (10). The paper by Alimzhanov *et al.* (11) in this issue of the *Proceedings* makes an important contribution to this field by examining the role of LT β in the development of secondary lymphoid tissue.

Early studies in TNF-deficient mice showed that TNF was the key mediator of septic shock induced by lipopolysaccharide and superantigens but also a key mediator of resistance to *Listeria monocytogenes* because p55 TNFR^{-/-} mice were resistant to endotoxic shock but susceptible to *Listeria* infection (12). Apart from their deficiency in effector functions, TNF^{-/-} mice exhibited also a deficiency in the organization of lymphoid tissue in that no primary lymphoid follicles were found in the spleen, and mature follicular dendritic cells were absent. Significantly, such mice could not form germinal centers after antigenic stimulation (13, 14).

Normally lymphoid organs are organized into compartments of T cell zones and B cell follicles. T cell zones are found in the paracortex of lymphnodes and periarteriolar sheets of the spleen whereas B cells form either resting primary follicles or activated secondary follicles—i.e., germinal centers. A third compartment of B cells exists in the marginal zone of the spleen (10). Until recently, little was known about the molecular mechanisms responsible for these structural organizations of lymphocytes around follicular dendritic cells in the case of primary or secondary follicles and around macrophages and metallophilic cells in the marginal zone of the spleen. In TNF^{-/-} mice the marginal zones in the spleen were expanded whereas follicles and follicular dendritic cells were absent (13). This may be due to a block of migration of marginal zone B cells, perhaps caused by the absence of adhesion receptors on the

marginal zone endothelial cells because TNF can induce the expression of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), MadCAM-1, and peanut agglutinin d (PNA-d) (15–18). Indeed in TNF^{-/-} mice MadCAM-1 could not be detected in splenic marginal zones (13). Thus, while T cells appear to migrate normally from marginal zones in TNF^{-/-} mice, B cell migration appears to be blocked. The absence of follicular dendritic cells (FDC) may in fact be caused by the absence of follicular B cells because generally B cell-deficient mice lack FDC (19, 20). This is well in line with the observation that transfer of normal bone marrow cells into TNF^{-/-} mice can restore normal lymphoid organ structure (21).

When LT α ^{-/-} mice were analyzed, an even more severe impairment of lymphoid organ structure was noticed: primary and secondary follicles were absent and FDC networks were lacking as in TNF^{-/-} mice, but in addition lymphnodes and Peyer's patches (PP) were absent (22, 23). Theoretically the more severe phenotype of LT α ^{-/-} mice could be due to either the absence of the LT α homotrimer or the LT α , β ₂ heterotri-




FIG. 1. TNF, LT, and their receptors.

Table 1. Phenotypes of mice deficient in TNF, LTs, or their receptors

	Splenic marginal zone	Primary lymphoid follicles	Secondary lymphoid follicles (germinal centers)	FDC networks	Lymphnode	PP	Thymus	Organ infiltrates
TNF = TNF α	Enlarged	Absent	Absent	Absent	Normal	Present	Normal	Absent
p55 TNFR		Absent	Absent	Absent	Normal	Present	Normal	Absent
p75 TNFR		Normal	Normal	Normal	Normal	Normal	Normal	Normal
LT α = TNF β	Disturbed	Absent	Absent	Absent	Absent	Absent	Normal	
LT β	Disturbed	Absent	Absent	Absent	Partially absent*	Absent	Normal	Massive \dagger

*Cervical and mesenteric lymphnodes present.

\dagger CD4 $^+$ cells and B cells.

mer that bind to the p55 or p75 TNFR and the LT β receptor, respectively (Fig. 1). However, because p55 TNFR $^{-/-}$ (24) and p75 TNFR $^{-/-}$ (25) mice develop lymphnodes and PP, it was more likely that the LT α $^{-/-}$ phenotype was caused by the absence of the LT α , β $_2$ heterotrimer binding to the LT β receptor. Indeed, it was shown in experiments employing a soluble LT β receptor-Fc fusion protein in pregnant mice that the genesis of lymphnodes and PPs but not that of mesenteric lymphnodes was inhibited in the embryos (26). These results were confirmed and extended in the papers by Alimzhanov *et al.* (11) as well as by Koni *et al.* (27) in LT β $^{-/-}$ mice.

LT β $^{-/-}$ mice, like LT α $^{-/-}$ mice, lacked peripheral lymphnodes, PPs, primary and secondary B cell follicles, as well as FDC. Unlike LT α $^{-/-}$ mice, however, these mice contained mesenteric and cervical lymphnodes, suggesting that the LT α homotrimer may have a special role in lymphoid organogenesis of the latter structures. A detailed analysis of the spleen in LT β $^{-/-}$ mice revealed the absence of MOMA $^+$ metallophilic macrophages in the spleen and the absence of MadCAM-I. In lymphnodes T and B cell zones appeared separated yet B cell follicles and FDC were absent. Here MadCAM-1 expression was found on what appeared to be flattened high endothelial venules. There were no abnormalities detected in primary lymphoid organs even though LT β was shown to be expressed in the thymus. In lung and liver a marked accumulation of lymphocytes was detected in perivascular areas consisting mostly of B cells and CD4 $^+$ T cells (Table 1). Finally, after immunization, germinal centers did not form but aggregates of PNA-binding cells could be detected.

The underlying molecular mechanisms responsible for the defects in lymphoid organogenesis and formation of germinal centers are not yet elucidated, but it appears likely that they involve the regulation of expression of various adhesion molecules as well as of inflammatory molecules that regulate migration of B cells as well as organization of FDC networks.

In summary, the TNF-like cytokine family of lymphotoxins has come a long way from initially being recognized as mediators of immune effector functions to the realization that these molecules play essential roles in the normal genesis of lymphoid organ structures.

1. Smith, C. A., Farrah, T. & Goodwin, R. G. (1994) *Cell* **76**, 959–962.
2. Li, C. B., Gray, P. W., Lin, P. F., McGrath, K. M., Ruddle, F. H. & Ruddle, N. H. (1987) *J. Immunol.* **138**, 4496–4501.
3. Conta, B. S., Powell, M. B. & Ruddle, N. H. (1985) *J. Immunol.* **134**, 2185–2190.
4. Powell, M. B., Conta, B. S., Horowitz, M. & Ruddle, N. H. (1985) *Lymphokine Res.* **4**, 13–26.
5. Müller, U., Jongeneel, C. V., Nedospasov, S. A., Fisher Lindahl, K. & Steinmetz, M. (1987) *Nature (London)* **325**, 265–267.

6. Browning, J. L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Chow, E. P., Hession, C., O’Brine-Greco, B., Foley, S. F. & Ware, C. F. (1993) *Cell* **72**, 847–856.
7. Pokholok, D. K., Maroulakou, I. G., Kuprash, D. V., Alimzhanov, M. B., Kozlov, S. V., Novobrantsseva, T. I., Turetskaya, R. L., Green, J. E. & Nedospasov, S. A. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 674–678.
8. Ware, C. F., Crowe, P. D., Grayson, M. H., Androlewicz, M. J. & Browning, J. L. (1992) *J. Immunol.* **149**, 3881–3888.
9. Ware, C. F., VanArsdale, T. L., Crowe, P. D. & Browning, J. L. (1995) *Curr. Top. Microbiol. Immunol.* **198**, 175–218.
10. Liu, Y. J. & Banachereau, J. (1996) *J. Exp. Med.* **184**, 1207–1211.
11. Alimzhanov, M. B., Kuprash, D. V., Kosco-Vilbois, M. H., Luz, A., Turetskaya, R. L., Tarakhovskiy, A., Rajewsky, K., Nedospasov, S. A. & Pfeffer, K. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 9302–9307.
12. Pfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M. & Mak, T. W. (1993) *Cell* **73**, 457–467.
13. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. (1996) *J. Exp. Med.* **184**, 1397–1411.
14. Pasparakis, M., Alexopoulou, L., Grell, M., Pfizenmaier, K., Bluethmann, H. & Kollias, G. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 6319–6323.
15. Pober, J. S., Lapiere, L. A., Stolpen, A. H., Brock, T. A., Springer, T. A., Fiers, W., Bevilacqua, M. P., Mendrik, D. L. & Gimbrone, M. A. (1987) *J. Immunol.* **138**, 3319–3324.
16. Cavender, D. E., Edelbaum, D. & Ziff, M. (1989) *Am. J. Pathol.* **134**, 551–560.
17. Sikorski, E. E., Hallmann, R., Berg, E. L. & Butcher, E. C. (1993) *J. Immunol.* **151**, 5239–5250.
18. Broudy, V. C., Harlan, J. M. & Adamson, J. W. (1987) *J. Immunol.* **138**, 4298–4302.
19. Cernay, A. R., Zinkernagel, R. M. & Groscurth, P. (1988) *Cell Tissue Res.* **254**, 449–454.
20. Kapasi, Z. F., Burton, G. F., Schultz, L. D., Tew, J. & Szakal, A. K. (1993) *J. Immunol.* **150**, 2648–2658.
21. Müller, M., Eugster, H. P., Le Hir, M., Shakhov, A., DiPadova, F., Maurer, C., Quesniaux, V. F. J. & Ryffel, (1996) *Mol. Med.* **2**, 247–255.
22. De Tongi, P., Goellner, J., Ruddle, N. H., Streeter, P. R., Fick, A., Mariathasan, S., Smith, S. C., Carlson, R., Shornick, L. P., Strauss-Schoenberger, J., Russel, J. H., Karr, R. & Chaplin, D. D. (1994) *Science* **264**, 703–707.
23. Banks, T. A., Rouse, B. T., Kerly, M. K., Blair, P. J., Godfrey, V. L., Kuklin, N. A., Bouley, D. M., Thomas, J., Kanangat, S. & Mucenski, M. L. (1995) *J. Immunol.* **155**, 1685–1693.
24. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., & Bluethmann, H. (1993) *Nature (London)* **364**, 798–802.
25. Erickson, S. L., de Sauvage, F. J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillet, N., Sheehan, K. C., Schreiber, R. D., Goeddel, D. V. & Moore, M. W. (1994) *Nature (London)* **372**, 560–563.
26. Rennert, P. D., Browning, J. L., Mebius, R., Mackay, F. & Hochman, P. S. (1996) *J. Exp. Med.* **184**, 1999–2006.
27. Koni, P. A., Sacca, R., Lawton, P., Browning, J. L., Ruddle, N. H. & Flavell, R. A. (1997) *Immunity* **6**, 491–500.